Clinical Trial Update: SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral regorafenib across selected sarcoma subtypes has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Liposarcoma
• Mesenchymal Chondrosarcoma
• Osteogenic Sarcoma
• Rhabdomyosarcoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Liposarcoma, Osteogenic Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07